Listen to this page using ReadSpeaker
Posts tagged FFB Clinical Research Institute

SparingVision Formed to Advance Sight-Saving Protein for RP

L to R: Florence Allouche Ghrenassia, PharmD, President, SparingVision; Frédérique Vidal, French Minister of Higher Education, Research and Innovation; José-Alain Sahel, MD, Co-Founder, SparingVision and Fondation Voir & Entendre; David Brint, and Chairman, Foundation Fighting Blindness; and Laure Reinhardt, Deputy CEO, Bpifrance

L to R: Florence Allouche Ghrenassia, PharmD, President, SparingVision; Frédérique Vidal, French Minister of Higher Education, Research and Innovation; José-Alain Sahel, MD, Co-Founder, SparingVision and Fondation Voir & Entendre; David Brint, Chairman, Foundation Fighting Blindness; and Laure Reinhardt, Deputy CEO, Bpifrance

The development of a vision-saving treatment for people with retinitis pigmentosa (RP) is getting a major boost thanks to the formation of the French biotech SparingVision to move it into a clinical trial and out to the international marketplace.

A spin-off of the Institut de la Vision, SparingVision was established to clinically develop and commercialize a protein known as rod-derived cone-viability factor (RdCVF). The emerging therapy performed well in several previous lab studies funded by the Foundation Fighting Blindness. SparingVision’s goal is to launch a clinical trial for the protein in 2019.
Continue Reading…

ARVO 2016: ProgSTAR, FFB-CRI’s Stargardt Disease Patient Study, Highlighted

Janet Cheetham, ProgSTAR's liaison to FFBOne of the hot topics at ARVO 2016 is ProgSTAR, the natural history study for people with Stargardt disease funded by the Foundation Fighting Blindness Clinical Research Institute (FFB-CRI). I caught up with Janet Cheetham, Pharm.D., the project’s liaison to FFB, to explain why the effort is important to therapy development. Having spent more than three decades in the development of retinal and ophthalmological treatments at Allergan, she brings a wealth of insight and knowledge to her role.
Continue Reading…